Taxoprexin® Treatment for Advanced Eye Melanoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00244816|
Recruitment Status : Completed
First Posted : October 27, 2005
Last Update Posted : January 24, 2018
To evaluate objective response rate and duration of response to weekly Taxoprexin®.
To evaluate the safety profile of weekly Taxoprexin® in this patient population.
To evaluate overall survival in the same patient population. To evaluate time to disease progression, and the time to treatment failure in patients with metastatic choroidal melanoma being treated with weekly Taxoprexin® Injection.
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Melanoma||Drug: Taxoprexin||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Open-Label Study of Weekly Taxoprexin® (DHA-paclitaxel) Injection as Treatment of Patients With Metastatic Uveal (Choroidal) Malignant Melanoma|
|Study Start Date :||October 2005|
|Study Completion Date :||April 2007|
- Response Rate
- Time to progression
- Time to treatment failure
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00244816
|United States, Texas|
|MD Anderson Cancer Center|
|Houston, Texas, United States, 77030-4009|
|Study Director:||Mark A Falone, MD||Luitpold Pharmaceuticals|